Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 307

1.

Efficacy, immunogenicity, and safety of two doses of a tetravalent rotavirus vaccine RRV-TV in Ghana with the first dose administered during the neonatal period.

Armah GE, Kapikian AZ, Vesikari T, Cunliffe N, Jacobson RM, Burlington DB, Ruiz LP Jr.

J Infect Dis. 2013 Aug 1;208(3):423-31. doi: 10.1093/infdis/jit174. Epub 2013 Apr 18.

2.

Epidemiology and evolution of rotaviruses and noroviruses from an archival WHO Global Study in Children (1976-79) with implications for vaccine design.

Rackoff LA, Bok K, Green KY, Kapikian AZ.

PLoS One. 2013;8(3):e59394. doi: 10.1371/journal.pone.0059394. Epub 2013 Mar 25.

3.

In Memoriam: Robert M. Chanock, MD, 1924–2010.

Kapikian AZ, Morens DM, Fauci AS.

J Infect Dis. 2011 Jan 1;203(1):3-5. No abstract available.

4.

Comparative evolution of GII.3 and GII.4 norovirus over a 31-year period.

Boon D, Mahar JE, Abente EJ, Kirkwood CD, Purcell RH, Kapikian AZ, Green KY, Bok K.

J Virol. 2011 Sep;85(17):8656-66. doi: 10.1128/JVI.00472-11. Epub 2011 Jun 29.

5.

Rotaviruses, Reoviruses, Coltiviruses, and Orbiviruses.

Kapikian AZ, Shope RE.

In: Baron S, editor. Medical Microbiology. 4th edition. Galveston (TX): University of Texas Medical Branch at Galveston; 1996. Chapter 63.

6.

Chimpanzees as an animal model for human norovirus infection and vaccine development.

Bok K, Parra GI, Mitra T, Abente E, Shaver CK, Boon D, Engle R, Yu C, Kapikian AZ, Sosnovtsev SV, Purcell RH, Green KY.

Proc Natl Acad Sci U S A. 2011 Jan 4;108(1):325-30. doi: 10.1073/pnas.1014577107. Epub 2010 Dec 20.

7.
8.

Evolutionary dynamics of GII.4 noroviruses over a 34-year period.

Bok K, Abente EJ, Realpe-Quintero M, Mitra T, Sosnovtsev SV, Kapikian AZ, Green KY.

J Virol. 2009 Nov;83(22):11890-901. doi: 10.1128/JVI.00864-09. Epub 2009 Sep 16.

9.

A longitudinal cohort study in calves evaluated for rotavirus infections from 1 to 12 months of age by sequential serological assays.

Cao D, Igboeli B, Yuan L, Kapikian AZ, Ayers JL, Abinanti FR, Hoshino Y.

Arch Virol. 2009;154(5):755-63. doi: 10.1007/s00705-009-0331-y. Epub 2009 Apr 3.

10.

To serotype or not to serotype: that is still the question.

Kapikian AZ, Hoshino Y.

J Infect Dis. 2007 Mar 1;195(5):611-4. Epub 2007 Jan 22. No abstract available.

PMID:
17262698
11.

Safety, efficacy, and immunogenicity of 2 doses of bovine-human (UK) and rhesus-rhesus-human rotavirus reassortant tetravalent vaccines in Finnish children.

Vesikari T, Karvonen AV, Majuri J, Zeng SQ, Pang XL, Kohberger R, Forrest BD, Hoshino Y, Chanock RM, Kapikian AZ.

J Infect Dis. 2006 Aug 1;194(3):370-6. Epub 2006 Jun 23.

PMID:
16826486
12.

Rotavirus vaccines.

Simonsen L, Taylor RJ, Kapikian AZ.

N Engl J Med. 2006 Apr 20;354(16):1747-51; author reply 1747-51. No abstract available.

PMID:
16625742
13.

Neonatal administration of rhesus rotavirus tetravalent vaccine.

Vesikari T, Karvonen A, Forrest BD, Hoshino Y, Chanock RM, Kapikian AZ.

Pediatr Infect Dis J. 2006 Feb;25(2):118-22.

PMID:
16462287
14.

A rotavirus strain isolated from pig-tailed macaque (Macaca nemestrina) with diarrhea bears a P6[1]:G8 specificity.

Hoshino Y, Honma S, Jones RW, Santos N, Nakagomi O, Nakagomi T, Kapikian AZ, Thouless ME.

Virology. 2006 Feb 5;345(1):1-12. Epub 2005 Oct 20.

15.

More on RotaShield and intussusception: the role of age at the time of vaccination.

Simonsen L, Viboud C, Elixhauser A, Taylor RJ, Kapikian AZ.

J Infect Dis. 2005 Sep 1;192 Suppl 1:S36-43.

PMID:
16088803
16.

A hexavalent human rotavirus-bovine rotavirus (UK) reassortant vaccine designed for use in developing countries and delivered in a schedule with the potential to eliminate the risk of intussusception.

Kapikian AZ, Simonsen L, Vesikari T, Hoshino Y, Morens DM, Chanock RM, La Montagne JR, Murphy BR.

J Infect Dis. 2005 Sep 1;192 Suppl 1:S22-9. Review.

PMID:
16088801
17.

Porcine rotavirus strain Gottfried-based human rotavirus candidate vaccines: construction and characterization.

Hoshino Y, Jones RW, Ross J, Kapikian AZ.

Vaccine. 2005 May 31;23(29):3791-9. Epub 2005 Mar 16.

PMID:
15893616
18.

A porcine G9 rotavirus strain shares neutralization and VP7 phylogenetic sequence lineage 3 characteristics with contemporary human G9 rotavirus strains.

Hoshino Y, Honma S, Jones RW, Ross J, Santos N, Gentsch JR, Kapikian AZ, Hesse RA.

Virology. 2005 Feb 5;332(1):177-88.

19.
20.
21.

Homotypic and heterotypic serum isotype-specific antibody responses to rotavirus nonstructural protein 4 and viral protein (VP) 4, VP6, and VP7 in infants who received selected live oral rotavirus vaccines.

Yuan L, Ishida S, Honma S, Patton JT, Hodgins DC, Kapikian AZ, Hoshino Y.

J Infect Dis. 2004 May 15;189(10):1833-45. Epub 2004 Apr 29.

PMID:
15122520
24.

Reappraisal of the association of intussusception with the licensed live rotavirus vaccine challenges initial conclusions.

Murphy BR, Morens DM, Simonsen L, Chanock RM, La Montagne JR, Kapikian AZ.

J Infect Dis. 2003 Apr 15;187(8):1301-8. Epub 2003 Apr 2. No abstract available.

PMID:
12696010
25.

Horizontal transmission of rhesus monkey rotavirus-based quadrivalent vaccine during a phase 3 clinical trial in Caracas, Venezuela.

Hoshino Y, Wagner M, Yan XY, Perez-Schael I, Kapikian AZ.

J Infect Dis. 2003 Mar 1;187(5):791-800. Epub 2003 Feb 24.

PMID:
12599053
28.

Detection and genotyping of human group A rotaviruses by oligonucleotide microarray hybridization.

Chizhikov V, Wagner M, Ivshina A, Hoshino Y, Kapikian AZ, Chumakov K.

J Clin Microbiol. 2002 Jul;40(7):2398-407.

29.

Ecological studies, rotavirus vaccination, and intussusception.

Kapikian AZ.

Lancet. 2002 Mar 23;359(9311):1065-6; author reply 1066. No abstract available. Erratum in: Lancet 2002 Aug 10;360(9331):494.

PMID:
11937208
30.

A predominant role for Norwalk-like viruses as agents of epidemic gastroenteritis in Maryland nursing homes for the elderly.

Green KY, Belliot G, Taylor JL, Valdesuso J, Lew JF, Kapikian AZ, Lin FY.

J Infect Dis. 2002 Jan 15;185(2):133-46. Epub 2002 Jan 3.

31.

Clinical evaluation of a single oral dose of human-bovine (UK) reassortant rotavirus vaccines Wa x UK (P1A[8],G6) and Wa x (DS-1 x UK) (P1A[8],G2).

Eichelberger MC, Sperber E, Wagner M, Hoshino Y, Dudas R, Hodgins V, Marron J, Nehring P, Casey R, Burns B, Karron R, Clements-Mann ML, Kapikian AZ.

J Med Virol. 2002 Mar;66(3):407-16.

PMID:
11793395
32.

Safety and immunogenicity of live attenuated quadrivalent human-bovine (UK) reassortant rotavirus vaccine administered with childhood vaccines to infants.

Clements-Mann ML, Dudas R, Hoshino Y, Nehring P, Sperber E, Wagner M, Stephens I, Karron R, Deforest A, Kapikian AZ.

Vaccine. 2001 Sep 14;19(32):4676-84.

PMID:
11535316
33.
34.

Transfusion-associated hepatitis not due to viral hepatitis type A or B. 1975.

Feinstone SM, Kapikian AZ, Purcell RH, Alter HJ, Holland PV.

Rev Med Virol. 2001 Jan-Feb;11(1):3-8; discussion 8-9. No abstract available.

PMID:
11241798
35.

Rhesus rotavirus-based quadrivalent vaccine is efficacious despite age, socioeconomic conditions and seasonality in Venezuela.

Egleé Pérez M, Glass R, Alvarez G, Pericchi LR, González R, Kapikian AZ, Pérez-Schael I.

Vaccine. 2000 Nov 22;19(7-8):976-81.

PMID:
11115724
36.

Rotavirus serotypes: classification and importance in epidemiology, immunity, and vaccine development.

Hoshino Y, Kapikian AZ.

J Health Popul Nutr. 2000 Jun;18(1):5-14. Review.

PMID:
11014764
37.

The discovery of the 27-nm Norwalk virus: an historic perspective.

Kapikian AZ.

J Infect Dis. 2000 May;181 Suppl 2:S295-302. Review.

PMID:
10804141
38.

Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants.

Clements-Mann ML, Makhene MK, Mrukowicz J, Wright PF, Hoshino Y, Midthun K, Sperber E, Karron R, Kapikian AZ.

Vaccine. 1999 Jun 4;17(20-21):2715-25.

PMID:
10418923
40.

Serotypic characterization of outer capsid spike protein VP4 of vervet monkey rotavirus SA11 strain.

Hoshino Y, Jones RW, Kapikian AZ.

Arch Virol. 1998;143(6):1233-44.

PMID:
9687880
41.

Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela.

Pérez-Schael I, Guntiñas MJ, Pérez M, Pagone V, Rojas AM, González R, Cunto W, Hoshino Y, Kapikian AZ.

N Engl J Med. 1997 Oct 23;337(17):1181-7. Erratum in: N Engl J Med 1998 Apr 2;338(14):1002.

42.

Expression and self-assembly of recombinant capsid protein from the antigenically distinct Hawaii human calicivirus.

Green KY, Kapikian AZ, Valdesuso J, Sosnovtsev S, Treanor JJ, Lew JF.

J Clin Microbiol. 1997 Jul;35(7):1909-14.

44.

Efficacy of a quadrivalent rhesus rotavirus-based human rotavirus vaccine aimed at preventing severe rotavirus diarrhea in infants and young children.

Kapikian AZ, Hoshino Y, Chanock RM, Pérez-Schael I.

J Infect Dis. 1996 Sep;174 Suppl 1:S65-72. Review.

PMID:
8752293
45.

Rotavirus vaccines: an overview.

Midthun K, Kapikian AZ.

Clin Microbiol Rev. 1996 Jul;9(3):423-34. Review.

46.

Serum rotavirus neutralizing-antibody titers compared by plaque reduction and enzyme-linked immunosorbent assay-based neutralization assays.

Ward RL, Kapikian AZ, Goldberg KM, Knowlton DR, Watson MW, Rappaport R.

J Clin Microbiol. 1996 Apr;34(4):983-5.

47.

Immunogenicity, safety and protective efficacy of one dose of the rhesus rotavirus vaccine and serotype 1 and 2 human-rhesus rotavirus reassortants in children from Lima, Peru.

Lanata CF, Black RE, Flores J, Lazo F, Butron B, Linares A, Huapaya A, Ventura G, Gil A, Kapikian AZ.

Vaccine. 1996 Feb;14(3):237-43.

PMID:
8920706
48.
49.

Classification of rotavirus VP4 and VP7 serotypes.

Hoshino Y, Kapikian AZ.

Arch Virol Suppl. 1996;12:99-111.

PMID:
9015107
50.

Overview of viral gastroenteritis.

Kapikian AZ.

Arch Virol Suppl. 1996;12:7-19. Review.

PMID:
9015097

Supplemental Content

Loading ...
Support Center